SubtlePET is DICOM image-processing software that reduces noise in FDG, amyloid, 18F-DOPA, 18F-DCFPyL, Ga-68 Dotatate, and Ga-68 PSMA PET images for radiologist or nuclear-medicine-physician review.
Clinical role
PET image denoising, reconstruction, or quantitative image-processing support before professional review.
Images and patients
PET/SPECT/Nuclear Medicine · Multi-region
Key limitation
The cleared tracer, reconstruction input, scanner, acquisition, dose, noise level, and quantitative use determine applicability; image-processing benefit is not a universal diagnostic-performance claim.
Overview status: Field-derived fact summary This section is assembled from the sourced field records below; it is not a source-reviewed editorial overview.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
Imaging and anatomyPET/SPECT/Nuclear Medicine · Multi-region
Workflow rolePET image denoising, reconstruction, or quantitative image-processing support before professional review.
Required inputSupported PET sinogram, list-mode, or reconstructed DICOM data and required CT or acquisition metadata.
Output and human actionProcessed PET image series, quantitative values, and visual identifiers for professional review.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
SubtlePET is DICOM image-processing software that reduces noise in FDG, amyloid, 18F-DOPA, 18F-DCFPyL, Ga-68 Dotatate, and Ga-68 PSMA PET images for radiologist or nuclear-medicine-physician review.
The cleared tracer, reconstruction input, scanner, acquisition, dose, noise level, and quantitative use determine applicability; image-processing benefit is not a universal diagnostic-performance claim.
K211964 describes a deep-neural-network residual noise-reduction workflow that receives DICOM 3.0 images, processes them, and forwards the results to a PACS or workstation. FDA software, image-quality, and functional testing supports the cleared processing workflow; no universal diagnostic-performance, dose-reduction, or tracer-independent claim is established.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
K211964 describes a deep-neural-network residual noise-reduction workflow that receives DICOM 3.0 images, processes them, and forwards the results to a PACS or workstation. FDA software, image-quality, and functional testing supports the cleared processing workflow; no universal diagnostic-performance, dose-reduction, or tracer-independent claim is established.
Sensitivity is not the primary endpoint for this system, reconstruction, segmentation, guidance, or quantitative function. Use the task-specific evidence below.
Reported specificity
Not applicable
Not applicable
Not applicable
Checked 2026-09-03
Specificity is not the primary endpoint for this system, reconstruction, segmentation, guidance, or quantitative function. Use the task-specific evidence below.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
K211964 FDA performance package for SubtlePET
DesignManufacturer software, image-quality, DICOM, and functional validation
PopulationSupported PET images using the labeled radiotracers and DICOM node workflow
Scopeexact submission
Tested versionSubtlePET
IndependenceSponsor or vendor study
K211964
Manufacturer evidence submitted for FDA clearance or approval; local clinical, technical, and workflow acceptance remains necessary.
3 unlinked candidate evidence records are retained for source review and excluded from this evidence display.
Safety and lifecycle
Postmarket record
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K211964 by exact submission identifier. This does not exclude product-family, later, or adverse-event information.
Public source
Exact FDA submission
Checked 2026-09-03
Exact-identifier review does not prove absence of all product-family safety signals.
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging, procedural, or surgical service line and verify payer, site-of-service, and coding assumptions independently.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Supported PET sinogram, list-mode, or reconstructed DICOM data and required CT or acquisition metadata.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: K211964 describes a DICOM 3.0 receive-process-forward workflow. The current Subtle Medical conformance material is family context; validate node configuration, identifiers, supported transfer syntaxes, routing, and rollback for the installed release.
Scope: Product family. Current vendor materials are product-family evidence for K211964; confirm the exact cleared version, enabled options, deployment, and local compatibility.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: Software integrated with the supported PET/CT scanner or deployed as a connected DICOM processing service.
Scope: Product family. Current vendor materials are product-family evidence for K211964; confirm the exact cleared version, enabled options, deployment, and local compatibility.
Confirm processing location, queue ownership, exclusions and exact AI build.
Unresolved route: Processed PET image series, quantitative values, and visual identifiers for professional review.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
Software integrated with the supported PET/CT scanner or deployed as a connected DICOM processing service.
Product family
Checked 2026-09-03
Current vendor materials are product-family evidence for K211964; confirm the exact cleared version, enabled options, deployment, and local compatibility.
K211964 describes a DICOM 3.0 receive-process-forward workflow. The current Subtle Medical conformance material is family context; validate node configuration, identifiers, supported transfer syntaxes, routing, and rollback for the installed release.
Product family
Checked 2026-09-03
Current vendor materials are product-family evidence for K211964; confirm the exact cleared version, enabled options, deployment, and local compatibility.
Subtle Medical's current compliance page lists an annual SOC 2 Type II + HIPAA security audit, and ISO 13485:2016 (valid until 2027-07-12) and ISO/IEC 42001:2023 (valid until 2028-07-17) certificates. The page gives no audit period or report scope, and the SOC 2 report was not read.
Vendor-wide
Checked 2026-10-25
Vendor-wide statement, not an independent attestation. It does not establish certificate or report scope for this exact release, expiry, data location, retention, identity and access, or incident-response terms for a deployed configuration. Obtain these from the vendor.
Only qualified nuclear medicine physicians, radiologists, technologists, and trained pet/ct professionals should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
Monitor by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: The cleared tracer, reconstruction input, scanner, acquisition, dose, noise level, and quantitative use determine applicability; image-processing benefit is not a universal diagnostic-performance claim.
Product family
Checked 2026-09-03
Current vendor materials are product-family evidence for K211964; confirm the exact cleared version, enabled options, deployment, and local compatibility.
K211964 describes a DICOM 3.0 receive-process-forward workflow. The current Subtle Medical conformance material is family context; validate node configuration, identifiers, supported transfer syntaxes, routing, and rollback for the installed release.
product family · checked 2026-09-03
Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally. Vendor statements are current product-family context; confirm the exact cleared release and installed options.
Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. The cleared tracer, reconstruction input, scanner, acquisition, dose, noise level, and quantitative use determine applicability; image-processing benefit is not a universal diagnostic-performance claim.
exact submission · checked 2026-09-03
Define stop-use, escalation, rollback, and revalidation triggers before production use.
Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.
product family · checked 2026-09-03
No exact-product price was found in the reviewed public material; vendor productivity claims are scenario inputs, not guaranteed local savings.
Monitor by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: The cleared tracer, reconstruction input, scanner, acquisition, dose, noise level, and quantitative use determine applicability; image-processing benefit is not a universal diagnostic-performance claim.
product family · checked 2026-09-03
Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes. Vendor statements are current product-family context; confirm the exact cleared release and installed options.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-04Last searched
25Fields reviewed
11Source classes checked
10Awaiting review PubMed leads
0Awaiting review trial leads
0Unreviewed FDA recall leads
Recovered from the prior exact-submission extraction and normalized under the current provenance rules. Exact FDA decision materials were reviewed for identity, indication, users, workflow, limitations, and submitted performance. Current vendor material is labeled product-family context where it does not establish the exact release. PubMed and ClinicalTrials.gov results are retained as candidate evidence with version applicability pending; CMS reimbursement context and exact-identifier openFDA postmarket results were also checked. Pricing, final security architecture, contracted services, enabled options, and local interoperability remain organization-specific evidence. Automated exact-name discovery found 10 PubMed and 0 ClinicalTrials.gov candidate records. Candidates require human product and version matching; zero candidates is not evidence that no studies exist. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads remain unpublished until a human confirms the exact product and tested version.
Source classes: fda ai list, fda decision summary, fda decision material, vendor product page, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-03 - Exact FDA submission
No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.
Authorized purpose: BIOGRAPH One with syngo MR XB10 combines metabolic or physiologic PET information with MR anatomy, MR-based attenuation correction, fused alignment, and support for treatment planning and interventions.
Authorized purpose: Voxel Dosimetry 3.1 calculates voxel-level absorbed-dose maps from nuclear-medicine images acquired after administration of FDA-approved therapeutic radiopharmaceuticals and supports single-time-point or time-series workflows.
Authorized purpose: syngo.via MI Workflows, Scenium, and syngo MBF provide PET, SPECT, nuclear-medicine, CT, and MR viewing, manipulation, quantification, longitudinal comparison, and analysis for oncology, cardiology, neurology, organ function, and selected radiation-planning support.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.